- Cited by
- 4 September 2021 | Social Psychiatry and Psychiatric Epidemiology, Vol. 56, No. 11
- 17 February 2020 | Military Medicine, Vol. 185, No. 7-8
- 3 February 2016 | Health Services Research, Vol. 51, No. 5
This study was funded in part by the Congressional Department of Defense Appropriation W81XWH-O7-1-0409/W81XWH-10-1-0579 sponsored by Congresswoman Marcy Kaptur of Ohio’s Ninth Congressional District.
Dr. Calabrese receives research support from, has consulted to, has served on the advisory boards of, or conducts continuing medical education supported by Abbott, AstraZeneca, the Brain & Behavior Research Foundation (formerly the National Alliance for Research on Schizophrenia and Depression), Bristol-Myers Squibb, Cephalon, Cleveland Foundation, Dainippon Sumitomo, Eli Lilly, EPI-Q, Inc., Forest, France Foundation, GlaxoSmithKline, Janssen, Johnson & Johnson, Lundbeck, Merck, NARSAD, Neurosearch, OrthoMcNeil, Otsuka, Repligen, Sanofi Aventis, Schering-Plough, Pfizer, Servier, Solvay, Stanley Medical Research Institute, Sunovion, Supernus, Synosia, Takeda, and Wyeth. The other authors report no competing interests.